<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875899</url>
  </required_header>
  <id_info>
    <org_study_id>CP0002</org_study_id>
    <nct_id>NCT02875899</nct_id>
  </id_info>
  <brief_title>Surfacer System to Facilitate Access in Venous Occlusions</brief_title>
  <acronym>SAVE</acronym>
  <official_title>Surfacer System to Facilitate Access in Venous Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bluegrass Vascular Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bluegrass Vascular Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single-arm, multicentre, international Registry of the Surfacer System for the
      treatment of patients with limited or diminishing upper body venous access or pathology
      impeding standard access methods.The purpose of this post-market Registry is to assess the
      standard of care and clinical outcomes of the Surfacer System used in clinical routine
      according to the approved commercial indications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, multicenter registry of the Surfacer System for patients
      with limited or diminishing upper body venous access or pathology impeding standard access
      methods. The need for long term access and lack of availability of veins has led to the
      development of the Surfacer System, which facilitates reliable and repeatable placement of
      central venous catheters and restores central venous access. Based on European legislation,
      this Registry is considered to be an observational study. No additional diagnostic or
      monitoring procedures as a result of the inclusion are applied to the patients. Available
      data will be collected in a protected database. Up to 30 patients will be enrolled in 5 sites
      in Europe. Patients requiring central venous access will be enrolled who meet inclusion and
      exclusion criteria and for whom the device is indicated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2017</start_date>
  <completion_date type="Actual">October 4, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>14 Days</target_duration>
  <primary_outcome>
    <measure>Absence of all acute safety and device related serious adverse event recorded on case report forms</measure>
    <time_frame>Procedure through discharge at 24 hours post procedure. Data will be presented through study completion, 1 year.</time_frame>
    <description>overall complication rate compared to safety data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability to place central venous access catheter using Surfacer system</measure>
    <time_frame>Procedure</time_frame>
    <description>performance evaluated by procedure time measured by time to create access</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surfacer system advancement of the exit wire outside the vein</measure>
    <time_frame>procedure</time_frame>
    <description>Ability to advance system from femoral vein to supraclavicular exit as measured by time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insertion of a standard central venous access catheter to deliver fluid or pharmacological agents</measure>
    <time_frame>procedure</time_frame>
    <description>introducing a standard central venous access catheter over the needle wire</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Venous Thrombosis</condition>
  <condition>Venous Thrombosis Upper Extremity</condition>
  <condition>Venous Thrombosis Upper Extremity Superficial Veins</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients requiring central venous access for:

          -  dialysis

          -  chemotherapy nutrition

          -  delivery of any pharmacological therapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: patients referred for placement of a central venous catheter

          -  patients with limited or diminishing upper body venous access

          -  pathology impeding standard access methods

          -  signed informed consent

        Exclusion Criteria:

          -  vulnerable subjects or incapable of giving consent

          -  contraindications to central venous access based on treating physicians opinion or
             standard of care

          -  occlusion of the right femoral vein

          -  occlusion of the iliac vein

          -  occlusion of the inferior vena

          -  acute thrombosis within a vessel (IVC, brachiocephalic and subclavian)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Minarsch, RT</last_name>
    <role>Study Director</role>
    <affiliation>Bluegrass Vascular</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Vienna</name>
      <address>
        <city>Vienna</city>
        <state>Waehringer Guertel 18-20</state>
        <zip>A 1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>D-50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schon Klinik</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Carlo Borromeo</name>
      <address>
        <city>Milan</city>
        <zip>20153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Elayi CS, Allen CL, Leung S, Lusher S, Morales GX, Wiisanen M, Aikat S, Kakavand B, Shah JS, Moliterno DJ, Gurley JC. Inside-out access: a new method of lead placement for patients with central venous occlusions. Heart Rhythm. 2011 Jun;8(6):851-7. doi: 10.1016/j.hrthm.2011.01.024. Epub 2011 Jan 13.</citation>
    <PMID>21237290</PMID>
  </reference>
  <reference>
    <citation>Frykholm P, Pikwer A, Hammarskj√∂ld F, Larsson AT, Lindgren S, Lindwall R, Taxbro K, Oberg F, Acosta S, Akeson J. Clinical guidelines on central venous catheterisation. Swedish Society of Anaesthesiology and Intensive Care Medicine. Acta Anaesthesiol Scand. 2014 May;58(5):508-24. doi: 10.1111/aas.12295. Epub 2014 Mar 5.</citation>
    <PMID>24593804</PMID>
  </reference>
  <reference>
    <citation>Baskin JL, Pui CH, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, Howard SC. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet. 2009 Jul 11;374(9684):159-69. doi: 10.1016/S0140-6736(09)60220-8. Review.</citation>
    <PMID>19595350</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

